Phosphodiesterase type 5 inhibitors for treating erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia: A comprehensive reviewFootnote

Peer review under responsibility of Arab Association of Urology.

References

• R.RosenJ.AltweinP.BoyleR.S.KirbyB.LukacsE.Meulemanet alLower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7)Eur Urol442003637649
   PubMed Web of Science ®Google Scholar
• A.OzayarA.E.ZumrutbasO.YamanThe relationship between lower urinary tract symptoms (LUTS), diagnostic indicators of benign prostatic hyperplasia (BPH), and erectile dysfunction in patients with moderate to severely symptomatic BPHInt Urol Nephrol402008933939
   PubMed Web of Science ®Google Scholar
• G.BrockG.BroderickC.G.RoehrbornL.XuD.WongL.ViktrupTadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunctionBJU Int1122013990997
   PubMed Web of Science ®Google Scholar
• A.SeftelR.RosenL.KuritzkyPhysician perceptions of sexual dysfunction related to benign prostatic hyperplasia (BPH) symptoms and sexual side effects related to BPH medicationsInt J Impot Res192007386392
   PubMed Web of Science ®Google Scholar
• A.D.SeftelJ.de la RosetteJ.BirtV.PorterV.ZarotskyL.ViktrupCoexisting lower urinary tract symptoms and erectile dysfunction: a systematic review of epidemiological dataInt J Clin Pract6720133245
   PubMed Web of Science ®Google Scholar
• K.HatzimouratidisE.AmarI.EardleyF.GiulianoD.HatzichristouF.Montorsiet alGuidelines on male sexual dysfunction: erectile dysfunction and premature ejaculationEur Urol572010804814
   PubMed Web of Science ®Google Scholar
• V.MironeA.SessaF.GiulianoR.BergesM.KirbyI.MoncadaCurrent benign prostatic hyperplasia treatment. impact on sexual function and management of related sexual adverse eventsInt J Clin Pract65201110051013
   PubMed Web of Science ®Google Scholar
• C.G.RoehrbornP.SiamiJ.BarkinR.DamiaoK.Major-WalkerI.Nandyet alThe effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT studyEur Urol572010123131
   PubMed Web of Science ®Google Scholar
• J.D.McConnellC.G.RoehrbornO.M.BautistaG.L.AndrioleJrC.M.DixonJ.W.Kuseket alThe long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasiaN Engl J Med349200323872398
   PubMed Web of Science ®Google Scholar
• G.CoronaG.RastrelliE.MaseroliG.BalerciaA.SforzaG.Fortiet alInhibitors of 5alpha-reductase-related side effects in patients seeking medical care for sexual dysfunctionJ Endocrinol Invest352012915920
   PubMed Web of Science ®Google Scholar
• H.J.ParkJ.E.WonS.SorsaburuP.D.RiveraS.W.LeeUrinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) and LUTS/BPH with erectile dysfunction in Asian men: a systematic review focusing on tadalafilWorld J Mens Health312013193207
   PubMedGoogle Scholar
• J.K.ParsonsBenign prostatic hyperplasia and male lower urinary tract symptoms. Epidemiology and risk factorsCurr Bladder Dysfunct Report52010212218
   PubMedGoogle Scholar
• J.T.WeiE.CalhounS.J.JacobsenUrologic diseases in America project: benign prostatic hyperplasiaJ Urol173200512561261
   PubMed Web of Science ®Google Scholar
• M.GacciI.EardleyF.GiulianoD.HatzichristouS.A.KaplanM.Maggiet alCritical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasiaEur Urol602011809825
   PubMed Web of Science ®Google Scholar
• M.KirbyC.ChappleG.JacksonI.EardleyD.EdwardsG.Hackettet alErectile dysfunction and lower urinary tract symptoms: a consensus on the importance of co-diagnosisInt J Clin Pract672013606618
   PubMed Web of Science ®Google Scholar
• K.E.AnderssonW.C.de GroatK.T.McVaryT.F.LueM.MaggiC.G.Roehrbornet alTadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of actionNeurourol Urodyn302011292301
   PubMed Web of Science ®Google Scholar
• K.T.McVaryErectile dysfunction and lower urinary tract symptoms secondary to BPHEur Urol472005838845
   PubMed Web of Science ®Google Scholar
• F.GiulianoS.UckertM.MaggiL.BirderJ.KisselL.ViktrupThe mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasiaEur Urol632013506516
   PubMed Web of Science ®Google Scholar
• S.UckertM.A.KuczykM.OelkePhosphodiesterase inhibitors in clinical urologyExp Rev Clin Pharmacol62013323332
   PubMed Web of Science ®Google Scholar
• P.WongN.LawrentschukD.M.BoltonPhosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worldsCurr Opin Urol192009712
   PubMed Web of Science ®Google Scholar
• M.OelkeA.BachmannA.DescazeaudM.EmbertonS.GravasM.C.Michelet alEAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstructionEur Urol642013118140
   PubMed Web of Science ®Google Scholar
• R.W.LewisR.SadovskyI.EardleyM.O’LearyA.SeftelW.C.Wanget alThe efficacy of tadalafil in clinical populationsJ Sex Med22005517531
   PubMed Web of Science ®Google Scholar
• R.C.RosenA.RileyG.WagnerI.H.OsterlohJ.KirkpatrickA.MishraThe International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunctionUrology491997822830
   PubMed Web of Science ®Google Scholar
• M.GacciG.CoronaM.SalviL.VignozziK.T.McVaryS.A.Kaplanet alA systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasiaEur Urol6120129941003
   PubMed Web of Science ®Google Scholar
• H.PorstK.T.McVaryF.MontorsiP.SutherlandA.Elion-MboussaA.M.Wolkaet alEffects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasiaEur Urol562009727735
   PubMed Web of Science ®Google Scholar
• M.OelkeF.GiulianoV.MironeL.XuD.CoxL.ViktrupMonotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trialEur Urol612012917925
   PubMed Web of Science ®Google Scholar
• C.F.DonatucciG.B.BrockE.R.GoldfischerP.J.PommervilleA.Elion-MboussaJ.D.Kisselet alTadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension studyBJU Int107201111101116
   PubMed Web of Science ®Google Scholar
• R.B.EgerdieS.AuerbachC.G.RoehrbornP.CostaM.S.GarzaA.L.Esleret alTadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind studyJ Sex Med92012271281
   PubMed Web of Science ®Google Scholar
• H.PorstC.G.RoehrbornR.J.SecrestA.EslerL.ViktrupEffects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studiesJ Sex Med10201320442052
   PubMed Web of Science ®Google Scholar
• G.A.BroderickG.B.BrockC.G.RoehrbornS.D.WattsA.Elion-MboussaL.ViktrupEffects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunctionUrology75201014521458
   PubMed Web of Science ®Google Scholar
• F.GiulianoM.OelkeA.JungwirthK.HatzimouratidisS.WattsD.Coxet alTadalafil once daily improves ejaculatory function, erectile function, and sexual satisfaction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and erectile dysfunction: results from a randomized, placebo- and tamsulosin-controlled, 12-week double-blind studyJ Sex Med102013857865
   PubMed Web of Science ®Google Scholar
• A.CasabeC.G.RoehrbornL.F.Da PozzoS.ZepedaR.J.HendersonS.Sorsaburuet alEfficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasiaJ Urol1912014727733
   PubMed Web of Science ®Google Scholar
• American Urological Association Practice Guidelines CommitteeAmerican Urological Association Guideline. Management of benign prostatic hyperplasia (BPH) 2003, updated 2006 and 20102010American Urological Association Education and Research, Inc. Available at: http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines.cfm?sub=bph [accessed 11 March 2015]
   Google Scholar
• Cialis [summary of product characteristics]. Eli Lilly. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000436/WC500026318.pdf [accessed 11 March 2015].
   Google Scholar
• H.PorstM.OelkeE.R.GoldfischerD.CoxS.WattsD.Deyet alEfficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studiesUrology822013667673
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Assessment report: Cialis. European Medicines Agency. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000436/WC500137787.pdf [accessed 11 March 2015].
   Google Scholar